Chinese cancer drug firm Akesobio’s US$330 million IPO – Hong Kong’s largest this year – is oversubscribed 639 times by city’s investors

The Hong Kong tranche of cancer drugs developer Akesobio’s HK$2.58 billion (US$330 million) initial public offering has been oversubscribed 639 times, making it the most popular biotechnology listing …
( read original story …)

---